Trial Information
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Sponsor: Apollomics, Inc.
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724